

■ Time Table

Day 1, February 18 (Thu)

As of February 12

	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22
Track 1										SY1 Implementing Strategies of Cancer Survivorship Care			ES29 Updated Treatment Strategy in mCSPC			
Track 2											SY4 Challenges of Combination Immunotherapy for Lung Cancer		ES09 Improving overall survival in EGFR+ NSCLC: established and future treatment strategies		SY7 PARP Inhibitor, Anti-angiogenesis, or Both? -Best Combination Treatments for Ovarian Cancer-	
Track 3										JS2 JASTRO/JSMO Joint Symposium What is the Best Collaboration Style between Radiotherapy and Immuno(Chemo)Therapy		ES07 The optimal use for immune checkpoint inhibitors in 1L NSCLC				
Track 4									Opening Remarks			ES01 Treatment Strategy for HR+/HER2- Metastatic Breast Cancer			SY6 MRD-guided Therapies for Hematologic Malignancies	
Track 5										SY5 Current Status and Future Perspectives of Immunotherapy for Advanced Esophageal Cancer		ES08 Treatment strategy of follicular lymphoma			SY8 Future Perspectives of Immunotherapy for mCRC	
Track 6										JS1 JCA/JASCO/JSMO Joint Symposium Cooperative Activities by 3 Academic Societies for Genomic Medicine		ES10 New Development of Cancer Cachexia - Role of Anamorelin -				
Track 7										SY2 Initiatives to Safely and Effectively Carry Out Cancer Treatment for the Elderly		ES11 Role of Niraparib for the Advanced or Relapsed Ovarian Cancer				
Track 8										EJS ESMO/JSMO Joint Symposium Liquid Biopsy for Clinical Implementation		ES12 Precision Oncology in GI cancers Clinical utility of comprehensive genomic profiling				
Track 9										SY3 High-grade Cancer Pain Treatment		ES13 Appropriate use and management of trastuzumab deruxtecan				
Track 10												ES02 Ovarian cancer treatment strategy up-to-date	ES14 Application of RWE based on the data of melanoma			
Track 11												ES03 What is the optimal treatment strategy for EGFR+ NSCLC?		PD1-1 Lung Cancer/ Immunotherapy	PD1-2 NSCLC/ Immunotherapy	
Track 12												ES04 Cancer Immunotherapy in Multiple Myeloma		PD2-1 Upper GI Tract (Gastric Cancer)	PD2-2 Lower GI Tract (Colorectal Cancer)	
Track 13												ES05 Neoantigens and Immune Checkpoint Inhibitors		PD3-1 Tb/Genomic Profiling/Genomic Medicine 1	PD3-2 Tb/Genomic Profiling/Genomic Medicine 2	
Track 14												ES06 Treatment Strategy for Treatment of Advanced Colorectal Cancer in the Real-World Era		PD4-1 COVID-19 and Cancer	PD4-2 NSCLC/ TKI	
Track 15																
Meeting 1 (Pre-registration Required)																
Meeting 2 (Pre-registration Required)																
Meeting 3 (Pre-registration Required)																
Meeting 4 (Pre-registration Required)																
	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22

Explanatory Notes

- SP =Special Session
- AJS =ASCO/JSMO Joint Symposium
- EJS =ESMO/JSMO Joint Symposium
- SJS =SIOG/JSMO Joint Symposium
- APJS =Asia-Pacific/JSMO Joint Symposium
- JS =Joint Symposium
- PSY =Presidential Symposium
- SY =Symposium
- ME =Meet the Experts
- MoS =Morning Seminar
- MeS =Medical Seminar
- ES =Evening Seminar
- PS =Presidential Session
- O =Oral Session
- MO =Mini-Oral Session
- PD =Poster Discussion Session

Simultaneous Interpretation (E&J)
 English Session
 Live Streaming Only
 Pre-recorded Video (streaming in the designated time only)